FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy

Journal of Controlled Release

Volumn 218, Issue , 2015, Pages 36-44

  Yang, Jiyuan ^a   Zhang, Rui ^a   Radford, D Christopher ^b   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b University of Utah   (United States)

Author keywords

Epirubicin; FRET; N (2 hydroxypropyl)methacrylamide (HPMA); Ovarian carcinoma

Indexed keywords

CHAINS; ENERGY TRANSFER; FLUORESCENCE; FLUOROPHORES; FREE RADICAL POLYMERIZATION; MAMMALS;

CHAIN TRANSFER AGENTS; EPIRUBICIN; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRET; METHACRYLAMIDES; OVARIAN CARCINOMA; POLYMERIC DRUG DELIVERY SYSTEM; REVERSIBLE ADDITION-FRAGMENTATION CHAIN TRANSFER POLYMERIZATION;

BIODEGRADABLE POLYMERS;

COPOLYMER; EPIRUBICIN; IODINE 125; N (2 HYDROXYPROPYL)METHACRYLAMIDE; ANTINEOPLASTIC ANTIBIOTIC; CARBOCYANINE; CYANINE DYE 3; CYANINE DYE 5; FLUORESCENT DYE; HYDROXYPROPYL METHACRYLATE; METHACRYLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG RELEASE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVARY CARCINOMA; POLYMERIZATION; PRIORITY JOURNAL; SYNTHESIS; THERAPY EFFECT; TUMOR REGRESSION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARBOCYANINES; CELL LINE, TUMOR; CELL SURVIVAL; EPIRUBICIN; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; METHACRYLATES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR BURDEN;

EID: 84943550254     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.045     Document Type: Article

References (47)

1. C. De Duve, T. De Barsy, B. Poole, A. Trouet, P. Tulkens, and F. van Hoof Lysosomotropic agents Biochem. Pharmacol. 23 1974 2495 2531
2. H. Ringsdorf Structure and properties of pharmacologically active polymers J. Polym. Sci. Polym. Symp. 51 1975 135 153
3. J. Kopeček Polymer - drug conjugates: origins, progress to date and future directions Adv. Drug Deliv. Rev. 65 2013 49 59
4. J. Yang, and J. Kopeček Macromolecular therapeutics J. Control. Release 190 2014 288 303
5. Y. Zhou, and J. Kopeček Biological rationale for the design of polymeric anti-cancer nanomedicines J. Drug Target. 21 2013 1 26
6. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
7. T. Minko, P. Kopečková, and J. Kopeček Comparison of the anticancer effect of free and HPMA copolymer-bound Adriamycin in human ovarian carcinoma cells Pharm. Res. 16 1999 986 996
8. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy, and on behalf of the Cancer Research Campaign Phase I/II Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates Clin. Cancer Res. 5 1999 83 94
9. C. Li, and S. Wallace Polymer-drug conjugates: recent development in clinical oncology Adv. Drug Deliv. Rev. 60 2008 886 898
10. R. Duncan, and M.J. Vicent Polymer therapeutics - prospects for 21st century: the end of the beginning Adv. Drug Deliv. Rev. 65 2013 60 70
11. P. Chytil, E. Koziolová, O. Janoušková, L. Kostka, K. Ulbrich, and T. Etrych Synthesis and properties of star HPMA copolymer nanocarriers synthesised by RAFT polymerisation designed for selective anticancer drug delivery and imaging Macromol. Biosci. 15 2015 839 850
12. P. Chytil, S. Hoffmann, L. Schindler, L. Kostka, K. Ulbrich, H. Caysa, T. Mueller, K. Mäder, and T. Etrych Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution J. Control. Release 172 2013 504 512
13. J. Yang, K. Luo, H. Pan, P. Kopečková, and J. Kopeček Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates React. Funct. Polym. 71 2011 294 302
14. K. Luo, J. Yang, P. Kopečková, and J. Kopeček Biodegradable multiblock N-(2-hydroxypropyl)methacrylamide copolymers via reversible addition-fragmentation chain transfer polymerization and click chemistry Macromolecules 44 2011 2481 2488
15. H. Pan, J. Yang, P. Kopečková, and J. Kopeček Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction Biomacromolecules 12 2011 247 252
16. R. Zhang, J. Yang, M. Sima, Y. Zhou, and J. Kopeček Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates Proc. Natl. Acad. Sci. U. S. A. 111 2014 12181 12186
17. R. Zhang, K. Luo, J. Yang, M. Sima, Y. Sun, M.M. Janát-Amsbury, and J. Kopeček Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel J. Control. Release 166 2013 66 74
18. H. Pan, M. Sima, J. Yang, and J. Kopeček Synthesis of long-circulating backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular weight dependent antitumor efficacy Macromol. Biosci. 13 2013 155 160
19. 1 conjugate Biomaterials 34 2013 6528 6538
20. S.V. Ontrust, L.R. Wiseman, and K.L. Goa Epirubicin: a review of its intravesical use in superficial bladder cancer Drugs Aging 15 1999 307 333
21. H. Havsteen, K. Bertelsen, C.C. Gadeberg, A. Jacobsen, C. Kamby, E. Sandberg, and L. Sengelov A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer Gynecol. Oncol. 63 1996 210 215
22. G.L. Plosker, and D. Faulds Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy Drugs 45 1993 788 856
23. M. Marquez, J. Du, M. Edgren, S. Nilsson, L. Lennartsson, J. Hiltunen, J.E. Westlim, T. Tammela, M. Raitanen, M. Laato, G. Jönsson, and A.R. Holmberg Development of dextran derivatives with cytotoxic effects in human urinary cancer cell lines Anticancer Res. 22 2002 741 744
24. F. Canal, M.J. Vicent, G. Pasut, and O. Schiavon Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates J. Control. Release 146 2010 388 399
25. G. Pasut, S. Scaramuzza, O. Schiavon, R. Mendichi, and F.M. Veronese PEG-epirubicin conjugates with high drug loading J. Bioact. Compat. Polym. 20 2005 213 230
26. H. Takahashi, K. Adachi, F. Yamaguchi, and A. Teramoto Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates Anticancer Res. 19 1999 4151 4155
27. B. Říhová Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates Adv. Drug Deliv. Rev. 61 2009 1149 1158
28. F. Greco, I. Arif, R. Botting, C. Fante, L. Quintieri, C. Clementi, O. Schiavon, and G. Pasut Polysialic acid as drug carrier: evaluation of a new polysialic acid-epirubicin conjugate and its comparison against established drug carriers Polym. Chem. 4 2013 1600 1609
29. J. Kopeček, and H. Bažilová Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization Eur. Polym. J. 9 1973 7 14
30. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs. US Patent 5037883 (1991).
31. V. Šubr, and K. Ulbrich Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups React. Funct. Polym. 66 2006 1525 1538
32. R. Duncan, H.C. Cable, P. Rejmanová, J. Kopeček, and J.B. Lloyd Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers Biochim. Biophys. Acta 799 1984 1 8
33. Y. Mitsukami, M.S. Donovan, A.B. Lowe, and C.L. McCormick Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT Macromolecules 34 2001 2248 2256
34. Y.L. Chiu, S.A. Chen, J.H. Chen, K.J. Chen, H.L. Chen, and H.W. Sung A dual-emission forster resonance energy transfer nanoprobe for sensing/imaging pH changes in the biological environment ACS Nano 4 2012 7467 7474
35. G.N. Hortobagyi, H.Y. Yap, S.W. Kau, G. Franchini, M.S. Ewer, S.P. Chawla, and R. Benjamin A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer Am. J. Clin. Oncol. 12 1989 57 62
36. Y. Yamamoto, I. Hyodo, Y. Koga, R. Tsumura, R. Sato, T. Obonai, H. Fuchigami, F. Furuya, M. Yasunaga, M. Harada, Y. Kato, A. Ohtsu, and Y. Matsumura Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models Cancer Sci. 106 2015 627 634
37. Q. Yang, T. Zhang, C. Wang, J. Jiao, J. Li, and Y. Deng Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133 + cancer stem-like cells Eur. J. Pharm. Biopharm. 88 2014 737 745
38. M. Tariq, M.A. Alam, A.T. Singh, Z. Iqbal, A.K. Panda, and S. Talegaonkar Biodegradable polymeric nanoparticles for oral delivery of epirubicin: in vitro, ex vivo, and in vivo investigations Colloids Surf. B: Biointerfaces 128 2015 448 456
39. X. Wang, X.C. Low, W. Hou, L.N. Abdullah, T.B. Toh, M.M.A. Rashid, D. Ho, and E.K.H. Chow Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells ACS Nano 8 2014 12151 12166
40. L. Seymour, K. Ulbrich, J. Strohalm, J. Kopeček, and R. Duncan The pharmacokinetics of polymer-bound Adriamycin Biochem. Pharmacol. 39 1990 1125 1131
41. S. Fogli, R. Danesi, A. Gennari, S. Donati, P.F. Conte, and M. Del Tacca Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer Ann. Oncol. 13 2002 919 927
42. Y. Zhou, J. Yang, J. Rhim, and J. Kopeček HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects J. Control. Release 172 2013 946 953
43. I. Matai, A. Sachdev, and P. Gopinath Self-assembled hybrids of fluorescent carbon dots and PAMAM dendrimers for epirubicin delivery and intracellular imaging ACS Appl. Mater. Interfaces 7 2015 11423 11435
44. S.J. Hauff, S.C. Raju, R.K. Orosco, A.M. Gross, J.A. Diaz-Perez, E. Savariar, N. Nashi, J. Hasselman, M. Whitney, J.N. Myers, S.M. Lippman, R.Y. Tsien, T. Ideker, and Q.T. Nguyen Matrix-metalloproteinases in head and neck carcinoma - cancer genome atlas analysis and fluorescence imaging in mice Otolaryngol. Head Neck Surg. 151 2014 612 618
45. T. Hussain, E.N. Savariar, J.A. Diaz-Perez, K. Messer, M. Pu, R.Y. Tsien, and Q.T. Nguyen Surgical molecular navigation with ratiometric activatable cell penetrating peptide for intraoperative identification and resection of small salivary gland cancers Head Neck 2015 10.1002/hed.23946
46. E.N. Savariar, C.N. Felsen, N. Nashi, T. Jiang, L.G. Ellies, P. Steinbach, R.Y. Tsien, and Q.T. Nguyen Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides Cancer Res. 73 2013 855 864
47. H. Nishikawa, Y. Ozaki, T. Nakanish, K. Blomgren, T. Tada, A. Arakawa, and K. Suzumori The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer Gynecol. Oncol. 92 2004 881 886